[1
]
From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N., J.R.W.);
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., J.C.C.); Washington
University and Siteman Cancer Center, St. Louis (N.L.B., A. Ghobadi); University of
Miami, Miami (L.J.L., K.V.K.); Stanford University, Stanford (D.B.M., R.L.), City
of Hope National Medical Center, Duarte (T.S.), University of California at Los Angeles,
Los Angeles (J.M.T.), University of California at San Diego, San Diego (J.E.C.), and
Kite Pharma, Santa Monica (A.B., J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.)
- all in California; Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore
Medical Center, Bronx (I.B.), and the University of Rochester School of Medicine,
Rochester (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center
(O.O.O.) and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical Center,
Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University Medical Center,
Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H., M.R.S.); Karmanos Cancer
Center, Wayne State University, Detroit (A.D.); University of Iowa Carver College
of Medicine, Iowa City (U.F.); Colorado Blood Cancer Institute, Denver (P.M.S.); Banner
M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); and Tel Aviv Sourasky Medical Center,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (I.A.).